Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy
Open Access
- 2 June 2020
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (12), 9291-9303
- https://doi.org/10.1002/jcp.29827
Abstract
Cytokine‐induced killer (CIK) cells represent an exceptional T‐cell population uniting a T cell and natural killer cell‐like phenotype in their terminally differentiated CD3+CD56+ subset, which features non‐MHC‐restricted tumor‐killing activity. CIK cells have provided encouraging results in initial clinical studies and revealed synergistic antitumor effects when combined with standard therapeutic procedures. We established the international registry on CIK cells (IRCC) to collect and evaluate clinical trials for the treatment of cancer patients in 2010. Moreover, our registry set new standards on the reporting of results from clinical trials using CIK cells. In the present update, a total of 106 clinical trials including 10,225 patients were enrolled in IRCC, of which 4,889 patients in over 30 distinct tumor entities were treated with CIK cells alone or in combination with conventional or novel therapies. Significantly improved median progression‐free survival and overall survival were shown in 27 trials, and 9 trials reported a significantly increased 5‐year survival rate. Mild adverse effects and graft‐versus‐host diseases were also observed in the studies. Recently, more efforts have been put into the improvement of antitumoral efficacy by CIK cells including the administration of immune checkpoint inhibitors and modification with chimeric antigen receptorc. The minimal toxicity and multiple improvements on their tumor‐killing activity both make CIK cells a favorable therapeutic tool in the clinical practice of cancer immunotherapy.Keywords
Funding Information
- Deutsche Krebshilfe
- China Scholarship Council
This publication has 95 references indexed in Scilit:
- Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical NephrectomyJournal of Immunology Research, 2013
- Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgeryExperimental and Therapeutic Medicine, 2013
- Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancerCancer Immunology, Immunotherapy, 2012
- Interleukin-6 Inhibits Regulatory T Cells and Improves the Proliferation and Cytotoxic Activity of Cytokine-induced Killer CellsJournal of Immunotherapy, 2012
- Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer CellsJournal of Immunology Research, 2012
- Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2011
- Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicityBlood, 2011
- Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cellsWorld Journal of Gastroenterology, 2011
- Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade culturesJournal of Translational Medicine, 2010
- Characterization of the recognition and functional heterogeneity exhibited by cytokine‐induced killer cell subsets against acute myeloid leukaemia target cellImmunology, 2009